Safety of shrimp peptide concentrate as a novel food pursuant to Regulation (EU) 2015/2283: (Scientific Opinion)
Research output: Contribution to journal › Journal article › Commissioned › peer-review
Standard
Safety of shrimp peptide concentrate as a novel food pursuant to Regulation (EU) 2015/2283 : (Scientific Opinion). / EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) ; Sjödin, Anders Mikael.
In: E F S A Journal, Vol. 16, No. 5, 5267, 16.05.2018.Research output: Contribution to journal › Journal article › Commissioned › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Safety of shrimp peptide concentrate as a novel food pursuant to Regulation (EU) 2015/2283
T2 - (Scientific Opinion)
AU - EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
AU - Sjödin, Anders Mikael
N1 - EFSA 2018 5267
PY - 2018/5/16
Y1 - 2018/5/16
N2 - Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on shrimp peptide concentrate as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is a peptide mixture obtained by an enzymatic proteolysis from northern shrimp (Pandalus borealis) shells and heads. The information provided on the composition, specifications, batch-to-batch variability, stability and production process of the NF is sufficient and does not raise safety concerns. The intention of the applicant is to use this NF as an ingredient in food supplements and to market it to adult consumers at a maximum proposed level of intake of 1,200 mg/day (corresponding to 17 mg/kg body weight (bw) per day for a 70 kg person). There are no concerns with regard to genotoxicity. The available human data do not raise safety concerns. Considering the no observed adverse effect level (NOAEL) of 2,000 mg/kg bw per day from a 90-day repeated-dose oral toxicity study, the maximum proposed level of intake and the nature ofthe NF, the Panel concludes that the margin of exposure (of 117) is sufficient. The Panel concludes that the NF, shrimp peptide concentrate, is safe to be used as a food supplement at the proposed maximum dose of 1,200 mg/day. The target population is adults. The Panel considered that the conclusion on the safety of the NF could not have been reached without the data from theunpublished study report on repeated-dose 90-day oral toxicity and from the unpublished study reports on two human studies.
AB - Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on shrimp peptide concentrate as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is a peptide mixture obtained by an enzymatic proteolysis from northern shrimp (Pandalus borealis) shells and heads. The information provided on the composition, specifications, batch-to-batch variability, stability and production process of the NF is sufficient and does not raise safety concerns. The intention of the applicant is to use this NF as an ingredient in food supplements and to market it to adult consumers at a maximum proposed level of intake of 1,200 mg/day (corresponding to 17 mg/kg body weight (bw) per day for a 70 kg person). There are no concerns with regard to genotoxicity. The available human data do not raise safety concerns. Considering the no observed adverse effect level (NOAEL) of 2,000 mg/kg bw per day from a 90-day repeated-dose oral toxicity study, the maximum proposed level of intake and the nature ofthe NF, the Panel concludes that the margin of exposure (of 117) is sufficient. The Panel concludes that the NF, shrimp peptide concentrate, is safe to be used as a food supplement at the proposed maximum dose of 1,200 mg/day. The target population is adults. The Panel considered that the conclusion on the safety of the NF could not have been reached without the data from theunpublished study report on repeated-dose 90-day oral toxicity and from the unpublished study reports on two human studies.
KW - Faculty of Science
KW - Shrimps (Pandalus borealis)
KW - Bioactive peptides
KW - ACE-inhibitors
KW - Novel food
KW - Safety
U2 - 10.2903/j.efsa.2018.5267
DO - 10.2903/j.efsa.2018.5267
M3 - Journal article
VL - 16
JO - E F S A Journal
JF - E F S A Journal
SN - 1831-4732
IS - 5
M1 - 5267
ER -
ID: 201005784